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ABSTRACT 
 
von Bonsdorff-Nikander, A.K., 2005. Studies on a cholesterol-lowering microcrystalline 
phytosterol suspension in oil 
 
Dissertationes bioscientiarum molecularium Universitatis Helsingiensis in Viikki,  
2/2005, 55 pp., ISBN 952-10-2289-2 (print) ISBN 952-10-2290-6 (pdf) ISSN 1239-9469 
 
Some cholesterol-lowering drugs have lately caused severe side-effects in humans and the 
potential use of phytosterols as an optional method of lowering serum cholesterol has been 
given considerable attention. Although the positive effect of phytosterols has been known for 
decades, their unpleasant gritty texture and the poor solubility has prevented their widespread 
use.  
In the present study, an oral phytosterol suspension was prepared by adding water to a 
supersaturated sterol in oil solution. The addition of water decreased the solubility in oil and 
microsized sterol crystals were formed. By changing the amount of sterol and/or water it was 
possible to control the crystal form, habit and size distribution. In the presence of water 
phytosterol recrystallised as needle-shaped hemihydrate or monohydrate crystals. Without 
added water, anhydrous plate-like crystals were achieved. Higher sterol concentrations 
resulted, due to supersaturation, in the formation of small crystals. By optimised process 
parameters, i.e. cooling temperature and stirring, it was also possible to achieve the desired 
crystal size for a so-called creamy suspension. Hardly any changes in crystal habit, size 
distribution or form were observed during storage of these suspensions for four months.  
Incorporation of the suspension into cholesterol-lowering products includes heating and thus 
the knowledge of structural and mechanical changes of the suspension during heating is of 
importance. Dehydration of phytosterol crystals in an oil suspension was, similarly to plain 
crystals, a two-phased process. The suspension became less elastic and the crystals started to 
dissolve at relatively low temperatures. 
A clinical study performed earlier using a similar microcrystalline suspension revealed a 
significant reduction of serum cholesterol levels. A dynamic in vitro study was performed to 
understand the mechanism by which phytosterols can inhibit cholesterol absorption in the 
small intestine. In addition to phytosterol, the choice of lipid in the suspensions was observed 
to have a significant effect on the solubilisation of sterols into the mixed micelles. The in 
vitro studies, in which medium chain length (MCT) and long chain length (LCT) lipids were 
compared, showed that phytosterols formulated in MCT efficiently displaced cholesterol 
from mixed micelles. Solubilisation into intestinal mixed micelles is a prerequisite for sterols 
to reach the site of absorption and thus cholesterol absorption is decreased. 
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1 INTRODUCTION 
  
The presence of cholesterol in human and other mammals is vitally important for the cell 
membrane function. However, an excessively high serum cholesterol concentration is a 
risk factor for cardiovascular diseases (CVD). In today’s world CVD is the leading cause 
of death in developed countries and is becoming one of the leading causes of death in 
developing countries as well (www.who.int, 2003). This means that despite the successful 
prevention of atherosclerosis, cardiovascular diseases are still responsible for one of 
every three cases of death. The combination of changed eating habits, the use of tobacco, 
and less physical activity are the main causes of the wide spread distribution of CVD. 
Genetic factors may also be a reason for enhanced serum cholesterol levels (Fuentes et 
al., 2000; Lind et al., 2002; Zuliani and Fellin, 2003). It has been demonstrated that a 
10% decline in total cholesterol is associated with a 20% risk reduction of coronary heart 
disease at the age of 70 and even lowers the risk by 50% at the age of 40 (Law et al., 
1994). Traditionally, high serum cholesterol levels have been normalised using 
cholesterol-lowering drugs. At the same time, the importance of dietary intake has been 
emphasised by the nutritionists.  
 
Selective inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA or 
statins), the rate-controlling enzyme of cholesterol synthetic pathway, are effective drugs 
but a very expensive method to treat hypercholesterolemia. Statins (e.g. mevastatin, 
lovastatin, cerivastatin and simvastatin) are able to lower serum total cholesterol by 
decreasing low density lipoprotein (LDL) cholesterol by 20%, even up to 55% (Chong et 
al., 2001; Blasetto et al., 2003; Endo, 2004). Some statins have, however, lately caused 
severe side effects which have resulted in major estimated revenue decreases for the 
pharmaceutical industry (Clark, 2003; Jamal et al., 2004). In August 2001, Bayer AG had 
to withdraw their cholesterol-lowering drug Lipobay®/Baycol® (cerivastatin) worldwide 
due to reports of side effects involving muscular weakness (rhabdomyolysis) (Maggini et 
al., 2004; www.investor.bayer.com, 2004). In less than a month, Bayer’s share had lost 
over 42% of its value (Bloomberg Terminal, 2004). The FDA (Food and Drug 
Administration) has received reports of serious muscle toxicity of another statin drug, 
Crestor® (rosuvastatin) by AstraZeneca (www.fda.com, 2004). At the moment the FDA is 
evaluating these reports and comparing the frequency of reports to the reports of other 
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statins. The importance of looking for optional methods of lowering cholesterol is 
therefore imminent. 
Studies of phytosterols, which are structurally related to cholesterol, date back to the 
1950s, when large amounts of phytosterols (10-15 g/day) were administrated in the form 
of a powder (Pollack, 1953; Farquhar et al., 1956). The unpleasant texture of phytosterols 
and the poor solubility in oil or water has caused several problems in preparation and 
administration, and thus prevented their widespread use (Miettinen, 2001).  
 
High-fat foods such as margarines and butters appear to be ideal vehicles for phytosterols 
and its saturated form phytostanol because of their strong hydrophobic nature (Mattson et 
al., 1982). Finnish science is at the forefront of development in sterols/stanols dietary 
products. The Raisio corporation launched the first commercialised phytostanol ester- 
containing cholesterol-lowering margarine, Benecol®, in 1995 (Miettinen et al., 1995). 
High-fat foods are contradictory to the current approaches of maintaining healthy diets 
and a healthy lifestyle. Therefore, the attempt has been to incorporate phytosterols into 
lower-fat foods (St-Onge and Jones, 2003). Because of the hydrophobic nature of 
phytosterols, the cholesterol-lowering efficacy in low-fat foods was thought to be minor. 
Studies, however, show that the effect of low-fat foods have a significant cholesterol-
lowering effect (Volpe et al., 2001; Nestel et al., 2001).  
In the middle of the 1990s a new method was developed, to make the use of phytosterols 
more accessible. A microcrystalline suspension in oil allows incorporation of up to 30% 
of phytosterols into a food product without any chemical reactions or additives. The 
extent of cholesterol-lowering in vivo is similar to those examined using phytosterol or 
phytostanol esters dispersed in high fat spreads. In 2003, the European Union’s Novel 
Foods Regulator gave its approval to begin marketing this suspension (Diminicol®) 
throughout the EU. Diminicol® received GRAS status (Generally Recognised As Safe) 
earlier the same year in the US by the FDA. The FDA also granted products containing 
Diminicol® the right to use the approved sterol heart health claim. 
Functional foods have no precise, universally accepted definition in general, but they can 
be considered food components (being nutrient or not), which affects one or a limited 
number of function of the body in a positive way, providing a health benefit beyond 
traditional nutritional value (Roberfroid, 2000; Palou et al., 2003). 
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The combination of statins and sterols/stanols has only been tested on a small scale so far. 
It appears that for patients who are taking statins and are in need of additional cholesterol 
lowering, the addition of sterols/stanols into the diet is more effective than the increase of 
statin doses (Katan et al., 2003). A wide study carried out in Finland (FINRISK 2002) 
revealed that of all patients who were aware of their high cholesterol levels, 19% used 
cholesterol-lowering medicines, 11% used cholesterol-lowering bread spreads and 5% 
combined both therapies (de Jong et al., 2004).  
 
2 REVIEW OF THE LITERATURE 
 
2.1 Phytosterols as cholesterol-lowering agents 
2.1.1 Composition, sources and consumption of phytosterols  
 
Phytosterols are a natural mixture of sterols containing a minimum 70% β-sitosterol 
(Ph.Eur. suppl. 4.1, 2001). They differ from cholesterol by the presence of an extra 
methyl or ethyl group on the cholesterol side chain at the C-24 position. The planar sterol 
structure with a hydroxyl group and a hydrophobic tail is characteristic for the molecular 
structure. Over 200 different types of phytosterols have been identified, of which β-
sitosterol, campesterol and stigmasterol are the major dietary sterols (Fig. 1) (Moreau, 
2002). Phytostanols are saturated phytosterols, that is, they have no double bonds in the 
sterol ring. 
 
 
 
 
 
 
 
 
 
 
     
         Figure 1. Structure of β-sitosterol (A), campesterol (B), stigmasterol (C) and cholesterol (D) 
 
HO 3 5
24
HO 3 5
24
HO 3 5
2422
HO 3 5
24
(A) (B)
(C) (D)
  
4
Phytosterols are important structural components of plant membranes, and they play a 
key role in plant cell membrane function just as cholesterol does in animal cell 
membranes (Quílez et al., 2003). Phytosterols are found in significant amounts in seeds, 
nuts, fruits and vegetables; however, the most concentrated source is vegetable oils 
(Ostlund, 2002). Since humans are not able to synthesize phytosterols, all phytosterols in 
the human body originate from dietary intake. As part of a normal healthy diet, most 
people eat 100-500 mg of phytosterol each day (Ostlund, 2002). Most of the phytosterols 
or phytostanols currently incorporated into foods are esterified to unsaturated 
sterol/stanol esters to increase lipid solubility, thus allowing maximal incorporation into a 
limited amount of lipid. Phytosterol or phytostanol intake from functional foods (e.g. 
bread spreads) is usually 1.5-3g/day. Phytosterol and phytostanol products reduce the 
serum concentration of total cholesterol by up to 15% and that of LDL cholesterol by up 
to 22% (Moghadasian and Frohlich, 1999; Ostlund, 2002; Christiansen et al., 2001a) (see 
also Table 1).  
Cholesterol derives the intestinal tract from two major sources. A normal Western diet 
provides 300-600 mg cholesterol per day to the intestine and an additional 1000-1500 
mg/day is derived from endogenous sources, mostly from the bile (Trautwein et al., 
2003).  
 
Table 1. Examples of different clinical studies with phytosterols incorporated in bread spread and the 
reduction in serum LDL cholesterol. 
 
Phytosterol 
(carrier) 
Dose 
(g/d) Time (wk) 
Changes in 
LDL  
cholesterol (%) 
Reference 
Sterol ester 
(margarine) 1.8 3 -6.5 Mussner et al., 2002 
Sterol (butter) 1.8 3 -11.3 Vanstone et al., 2002 
Sterol  (margarine) 1.5 
3.0 
26 
26 -11.6 Christiansen et al., 2001a 
Sterol (butter) 1.0 4 -6.2 Volpe et al., 2001 
Sterol ester (fat 
spread) 2.5 8 -10.0 Neil et al., 2001 
Sterol ester (butter) 2.4 4 -12.2 Nestel et al., 2001 
Sterol ester 
(margarine) 2.1 4 -10.4 Hallikainen et al., 2000 
 
At first, animal and human studies showed that phytostanols inhibit cholesterol 
absorption and lower serum cholesterol more effectively than phytosterols (Sugano et al., 
1977, Heinemann et al., 1986; Heinemann et al., 1991). However, more recent studies 
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reveal no difference between phytosterols and phytostanols in the lowering of the 
absorption or the serum concentration of cholesterol (Hallikainen et al., 2000; Law, 
2000).  
The daily dose of sterol/stanol food products is often divided into 2-3 portions, although 
it has been shown that a large single daily dose is equally effective (Plat et al., 2000). It is 
likely that part of the phytosterol is precipitated in the intestine and re-solubilised during 
lipolysis of lipids contained in the food ingested at a later time. Lately it has been 
revealed that phytosterols may also have an effect on cholesterol metabolism inside the 
enterocytes.  
2.1.2 Safety of phytosterols and phytostanols 
 
The current opinion is that phytosterols are safe when added to the diet because they are 
found in natural foods. Phytosterol and phytostanol-enriched foods, which decrease 
serum cholesterol levels, are among the first examples in Europe of functional foods 
whose safety has been evaluated following the legislation applied to Novel Foods (SCF 
2000, 2003).  
However, some observations of decreased levels of the absorption of other lipid soluble 
components such as vitamins and antioxidants are of concern (Plat et al., 2000; Mensink 
et al., 2002). Some randomised studies report that phytosterols and phytostanols lower 
serum concentration of β-carotene by up to 25%, concentrations of α-carotene by 10%, 
and concentration of vitamin E by 8% (Weststrate and Meijer, 1998; Hallikainen et al., 
1999; Gylling and Miettinen, 1999). The serum concentration of vitamin D and retinol 
has been observed to be unaffected (Gylling and Miettinen, 1999). Contrary to the above, 
several studies report no significant effects on serum lipid soluble vitamins (Christiansen 
et al., 2001a; Davidson et al., 2001; Volpe et al., 2001 Raieni-Sarjaz et al., 2002). Thus 
the relevance of the observed changes is not yet adequately known and warrants further 
attention. A part of the reported reduction can be explained by a decreased amount of 
LDL particles in the circulation, which transports these lipid-soluble antioxidants (de 
Jong et al., 2003). Phytosterols and phytostanols may also interfere with the incorporation 
into the mixed micelles. Furthermore, phytosterol esters did not substantially affect 
vitamin K-dependent hemostasis on individuals that underwent warfarin therapy, 
suggesting that, at least in short term studies, vitamin K status was not affected by the 
consumption of phytostanols (Nguyen, 1999). Phytosterols have shown no evidence of in 
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vitro mutagenic activity (Wolfreys and Hepburn, 2002). Safety data of phytosterols and 
phytostanols collected for a period of more than five years in Finland and two years in the 
US show no evidence of hazard adverse effects (Katan et al., 2003). 
2.1.3 Phytosterol absorption 
 
The amounts of absorption vary among the individual phytosterols due to both the sterol 
nucleus and the length of the side chain (Ostlund, 2002). In humans, less than 2% of the 
ingested phytosterols is absorbed. β-sitosterol, which is the most extensive phytosterol, is 
the least well absorbed (0.5%) due to its high hydrophobicity. The absorption of 
phytosterols, therefore, is considerably smaller than that of cholesterol, which can be up 
to 60% (Ostlund et al., 2002). Total serum phytosterol concentrations in healthy adults 
range from 7 µmol/L to 24 µmol/L (Moghadasian, 2000).  
Due to the hydrophobicity of the sterols, solubilisation into intestinal mixed micelles is a 
prerequisite for reaching the site of absorption. Phytosterols are solubilised under the 
same conditions that exist for cholesterol and other lipids (Ros, 2000; Moghadasian, 
2000). Solubilisation into mixed micelles is greatly enhanced in the presence of products 
of triglyceride digestion (monoglycerides (MG) and fatty acids (FA)) (Fig. 2) (Carey and 
Small, 1970; Ros, 2000).  
 
Mechanism of dietary mixed micelle formation 
 
The mechanical digestion of lipids starts as early as in the mouth and continues in the 
stomach with emulsification. Chewing breaks down large pieces of fat into smaller sizes 
whereafter the peristaltic movements further grind the smaller pieces into a creamy 
emulsion (chyme). The purpose of emulsification is to increase the surface area of the 
lipid droplets, thereby increasing the area on which the digestive enzymes can act 
effectively. Lingual lipase probably has a minor effect on lipolysis, unlike gastric lipase, 
which hydrolyses approximately one out of four triglycerides molecules during digestion 
of a meal (Embleton and Pouton, 1997; Ros, 2000). The gastric (and lingual) lipase is 
responsible for the hydrolysis of triglyceride (TG) to the corresponding diglyceride (DG) 
and fatty acid (FA). The presence of lipolysis products (mainly FA) in the duodenum 
stimulates the release of the hormone cholecystokinine, which then induces the secretion 
of bile acids from the gallbladder and the release of pancreatic juice containing lipases. 
The sudden increase in pH in the duodenum causes an abrupt change in the physical 
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behaviour of the fatty acids contained in the emulsion droplets. These become partly 
charged and migrate to the interface of the emulsion droplet, inhibiting the binding of the 
principal lipolytic enzyme, pancreatic lipase. The effect of co-lipase is to anchor 
pancreatic lipase to the surface of the emulsified lipid droplet. By the enzymatic action of 
pancreatic lipase on TG droplets, the corresponding 2-monoglyceride and two fatty acids 
are produced. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic model of intestinal lipid digestion and trafficking of lipolysis products. D=drug or 
other compound, BS= Bile salts, FA= Fatty acid, PL= Phospholipid, MG= Monoglycerides, DG= 
Diglyceride (partly adapted from Porter et al., 2004). 
 
Bile, containing a mixture of bile salts and phospholipids, plays a fundamental role in the 
solubilisation of lipid digestion products and other poorly water-soluble compounds. A 
typical concentration of bile salts in the fasted intestine is 4-6 mM, compared to post-
prandial concentrations of 10-20 mM (Ladas et al., 1984; Armand et al., 1996; 
Humberstone and Charman, 1997). When the concentration of bile salts in the intestine 
exceeds critical micellar concentration (cmc), lipids and bile salts interact spontaneously 
to form polymolecular aggregates, micelles. Lipids (digestion products) promote micellar 
swelling and therefore increase the capacity of the micelles to solubilise 
lipophilic/hydrophobic compounds (Porter and Charman, 2001). When the amount of 
lipid digestion products in the aqueous phase increases, while the amount of bile does 
D D D D
D
D
D
D
D
D
D
D D
D
D D
D
BS, FA, PL, MG, DG Enterocyte
Proximal small intestine
Formation of dietary mixed micelles
Mouth Stomach
Formation of crude emulsion Formation of fine emulsion
Emulsification
Solubilisation
+Lipolysis
Triglyceride 2 monoglyceride Fatty acid
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not, the lipolytic products accumulate on the surface of the lipid droplet. This results in 
the shedding of lipolytic products in the form of multilamellar liquid crystalline 
structures. These structures are normally dissolved quickly into mixed micelles at the 
appropriate bile salt concentration (Ros, 2000). Thus, higher bile salt concentrations 
improve lipid digestion through effective solubilisation of lipolytic products, leading to 
an abundance of swollen micellar structures. This promotes the solubilisation of sterols or 
other lipophilic compounds. 
 
Influx/efflux of sterols in the enterocytes 
 
The transfer of sterols/stanols from the mixed micelles into the enterocytes has long been 
considered a passive process. Recently it has been suggested that a specific protein in 
jejunal enterocytes called Niemann-Pick C1 Like 1 (NPC1L1) shuttle system facilitates 
sterol absorption from the intestinal lumen through the brush border membrane of the 
enterocyte (Davis et al., 2004; Altmann et al., 2004). The ATP-binding cassette (ABC) 
transporters, ABCG5 and ABCG8, are two quite recently discovered half-transporters, 
strongly present in the liver and the intestines. They are involved in the excretion of 
sterols back into the intestinal tract (Berge et al. 2000; Chen, 2001; Albrecht et al., 2002; 
Trautwein et al., 2003, Ostlund, 2004). ABC transporters are proteins that use ATP as a 
source of energy to transport substrates between different cellular compartments and out 
from the cell (Oram and Lawn, 2001). In a similar way another ATP-binding cassette A1 
(ABCA1) is involved in the transport of excess tissue sterol from the enterocytes into the 
lumen. Mutations in any of the ABCG5 and ABCG8 genes are associated with 
sitosterolemia. Sitosterolemia (also known as phytosterolemia) is a rare genetic disorder, 
(one in 6 million people), where patients who fail to excrete sterols into bile have 
extremely high concentrations of serum phytosterols, particularly sitosterol, in serum and 
tissues (Moghadasian, 2000; Lu et al., 2001). Patients with sitosterolemia also 
hyperabsorb cholesterol and are usually hypercholesterolemic (Berge et al., 2001; Lee et 
al., 2001). 
 
Esterification and incorporation into chylomicrons 
 
Absorbed free cholesterol is esterified by acyl-coenzyme A cholesterol acyltransferase 
(ACAT) inside the enterocyte. Only the esterified form is incorporated into chylomicrons 
and excreted into the circulation. There are several potential explanations for the low 
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phytosterol (phytostanol) absorption compared to that of cholesterol.  Phytosterols have a 
low affinity for ACAT and are therefore poorly esterified (Field and Marthur, 1983). 
Since only the esterified form is incorporated into chylomicrons, and further excreted into 
the circulation, the concentration in circulation remains low.  
2.1.4 Phytosterol mechanisms of action on intestinal cholesterol absorption 
 
The mechanism of the cholesterol-lowering activity of phytosterols is not completely 
understood but several theories have been proposed (Fig. 3). Phytosterols are claimed to 
inhibit the absorption of dietary and reabsorption of endogenous cholesterol from the 
gastrointestinal tract. Additionally, phytosterols seem to enhance the efflux of excess 
absorbed cholesterol. Consequently, the excretion of cholesterol in the faeces leads to 
decreased serum levels of this sterol.  
 
Competition between cholesterol and phytosterols for solubilisation in mixed micelles 
 
Cholesterol has to be solubilised within mixed micelles, containing bile-salts and 
phospholipids, in order to reach the site of absorption and further be absorbed into 
circulation. Mixed micelles have a limited capacity to solubilise hydrophobic molecules. 
In vitro and in vivo studies suggest that phytosterols have a greater affinity for micelles 
and can therefore displace cholesterol from the mixed micelles (Ikeda and Sugano, 1983; 
Mel´nikov et al., 2003b; Trautwein et al., 2003). Armstrong and Carey reported that 
phytosterols, due to their increased hydrophobicity compared to cholesterol, have a lower 
solubility in, but a higher affinity for bile acid micelles than does cholesterol (1987).  
 
Co-crystallisation of phytosterols and cholesterol  
 
One potential mechanism of lowering the intestinal cholesterol absorption is co-
crystallisation of cholesterol and phytosterols in the gastrointestinal tract, forming poorly 
absorbable mixed crystals (Christiansen et al., 2001b; Christiansen et al., 2003). Both 
phytosterol and cholesterol are, in a free form, sparingly soluble in oil (3 g/100 ml at 37 
°C in presence of water) and practically insoluble in water (~0.2 mg/100 ml) (Jandacek et 
al., 1977). As early as in the 1950s Davis noticed that cholesterol and β-sitosterol formed 
a new crystal form when the sterols were precipitated in methanol (1955). Co-
crystallisation of phytosterols and cholesterol in the gastrointestinal tract should lead to 
the reduction of intestinal cholesterol uptake since the solubility of the new crystal is 
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considerably lower than that of cholesterol.  Recently, however, Mel´nikov et al. (2003a; 
2003b) reported that it is unlikely that the formation of mixed crystals largely affects the 
intestinal absorption of cholesterol in vivo. This is due to the relatively high solubility of 
cholesterol, phytosterol and phytostanol in products of fat lipolysis. 
 
 
Figure 3. Phytosterols 
displace cholesterol from 
intraluminal intestinal 
micelles, reducing 
cholesterol absorption by the 
brush border membrane. The 
exact mechanism by which 
sterols are absorbed to 
enterocytes is not fully 
known. The transfer of 
sterols/stanols has long been 
considered a passive process. 
Recently the Niemann-Pick 
C1 Like 1 (NPC1L1) shuttle 
system was found to be the 
intestinal phytosterol and 
cholesterol transporter. The 
ATP-binding cassette 
transporters (ABCG5, 
ABCG8 and ABCA1) are 
similarly involved in the 
efflux of excess sterol from 
the enterocytes back into the 
intestinal lumen. 
Phytosterols may also reduce 
the esterification rate of 
cholesterol inside the 
enterocytes through 
inhibition of acyl-coenzyme 
A cholesterol acyltransferase 
(ACAT). Only the esterified 
form (cholesterol ester CE, 
phytosterol ester, PE) is 
incorporated into 
chylomicrons and secreted 
into circulation.  
 
 
Decreased cholesterol influx from and increased cholesterol efflux back into the 
intestinal lumen   
 
Recently it has been stated that the Nieman Pick C1 L1 (NPC1L1) shuttle system plays a 
fundamental part in the regulation of cholesterol influx into the enterocytes. However, it 
appears that these transport systems are unable to differentiate between cholesterol and 
phytosterols. Thus an increased amount of phytosterol in the intestine results in reduced 
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cholesterol in the enterocyte and further reduced cholesterol in circulation. In the same 
way the cellular ATP-binding cassette transporters (ABCG5, ABCG8, ABCA1) are 
involved in the efflux of excess sterol from the enterocytes back into the intestinal lumen 
(Plat and Mensink, 2002; de Jong et al., 2003).  
 
Inhibition of ACAT activity 
 
Another proposed cholesterol-lowering mechanism of phytosterols is the possible 
reduction of the esterification rate of cholesterol inside the enterocytes through inhibition 
of acyl-coenzyme A cholesterol acyltransferase, ACAT (Chen, 2001; de Jong et al., 2003; 
Trautwein, 2003). ACAT reduces the intracellular free cholesterol concentration by 
transforming it into cholesteryl ester. Phytosterols might challenge ACAT activity and 
reduce the absorption of cholesterol because of the high intracellular free sterol 
concentration. Cholesterol has to be incorporated into chylomicrons before it is secreted 
into the lymph. Up to 80% of the cholesterol incorporated in the chylomicrons is in an 
esterified form (Ikeda et al., 1988; Dawson and Rudel, 1999).  
 
2.2 Theory of suspensions and crystal properties 
 
A suspension can be defined as a heterogeneous system in which one phase, a solid, is 
finely divided and dispersed in the other, generally a liquid (the dispersion medium). 
Drugs and other compounds are dispensed as suspensions for different reasons, the most 
common being poor solubility in water, oil or an organic liquid (Falkiewicz, 1988). The 
large surface area of the suspended compound ensures a high degree of bioavailability for 
absorption. Suspensions may also be used to mask the taste of a bitter or unpleasant 
compound. Pharmaceutical suspensions are prepared mainly for oral use, topical 
administration, parenteral use or inhalation therapy (Nash, 1996). Other applications for 
suspensions are e.g. cosmetics, foods and household products.  
2.2.1 Properties of solid particles 
 
The number of particles and different crystalline modifications of the solid material, such 
as crystalline, amorphous or solvated forms, can affect certain properties of a suspension, 
for example solubility, dissolution rate and chemical stability (Haleblian, 1975). 
Crystalline solid is a state where structural units, formed by molecules, atoms or ions, are 
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arranged in a regular, repeating array (Vippagunta et al., 2001). Within a specific crystal, 
each unit cell is the same size and contains the same number of molecules. The unit cell 
can be thought of as a box, which when stacked together three-dimensionally, produces 
the crystal lattice. The simplest and most symmetric of these is the cubic system. The 
other six systems are the hexagonal, tetragonal, trigonal, orthorhombic, monoclinic and 
the triclinic systems.  
When a material is in solid state but consists of disordered arrangements of molecules, it 
is said to be amorphous (glass state). Amorphous solids have properties very different 
from the crystal form, no melting point and no definitive x-ray pattern. Consequently, 
they have zero crystallinity. The crystallinity can be described as the degree of 
crystallinity which is the ratio of the crystalline to amorphous parts in a substance.  
 
Crystals in a suspension are larger than those in colloids or solutions; they are visible 
under a microscope, and some can be seen with the naked eye. The particle size 
distribution of the suspended phase is one of the most important parts in the formulation 
and stability of a suspension (Nash, 1996). A fine particle size is important to ensure a 
slow rate of sedimentation of the suspended particles and better resuspendability. While 
most of the existing suspensions have particle sizes in the micron range, technology 
development in recent years has extended the range down to the submicron region. One 
of the advantages of nanosized crystals is the possibility of intravenous administration 
(Merisko-Liversidge et al., 1996). When particle size grows beyond ~1 µm, the system is 
called coarse suspension (Nash, 1988). The upper limit for a suspendable solid particle in 
coarse pharmaceutical suspensions is from 50 to 75 µm. However, particles larger than 5 
µm will cause a gritty texture when administered in the eye and particles over 25 µm 
might block the needle in parenteral use. The optimum particle size for a so-called 
creamy suspension administered orally lies, according to the food industry, between 10 
µm and 50 µm (Viaene and Januszewska, 1999; Kilgast and Clegg, 2002).  
 
Research has focused more on crystal size distribution than on crystal habit, which is 
another critical property of a crystalline solid in suspensions. The crystal habit 
particularly affects the stability of suspensions and their usage. Regarding the physical 
stability, needle-shaped crystals are preferred, since they stay suspended better than 
prismatic crystals (La Manna, 1985). The crystal habit, or overall shape of the crystal, 
depends on internal factors (e.g. structure and bonds) and external factors (e.g. 
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supersaturation and solution composition) (Boistelle and Astier, 1988). The shapes of 
particles are classified into ten classes according to British Standards (BS 2955).  Crystals 
are, however, usually classified according to the seven general systems as acicular 
(needle), prismatic, pyramidal, tabular, equant, columnar and lamellar types (Fig. 4). 
Acicular, prismatic and plate-like crystals are common habits for recrystallised 
compounds (Anwar et al., 1989; Agafonov et al., 1991).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Some crystal habits A. tabular, B. platy, C. prismatic, D. acicular and E. bladed. 
 
Different crystal structures of the same compound (polymorphism) can also be a factor in 
suspension technology. Polymorphism is defined as the ability of a compound to 
crystallise in at least two different crystal forms (Haleblian and McCrone, 1969). 
Polymorphs of a certain substance usually have different physicochemical properties, 
such as melting point, solubility and density. Polymorphism may thus have an effect on 
the bioavailability, manufacturability, and stability of the product. Pseudopolymorphs, 
also known as solvates, are crystalline solids that include solvent molecules within the 
crystal structure (Vippagunta, 2001). The differences between polymorphs and 
pseudopolymorphs are significant. Whereas polymorphs are different crystal structures of 
the same molecules, pseudopolymorphs, on the other hand, are crystals of the same 
molecule with different numbers of solvent molecules. If the solvent molecule is water, 
these crystals are termed hydrate. The liberation of water molecules or organic solvents 
from crystals is dependent on environmental conditions such as temperature, humidity 
and pressure. Crystalline hydrates can be classified into three categories (Morris and 
A B
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Rodrigues-Hornedo, 1992). The first category (class 1) is the isolated lattice site hydrates, 
where the water molecules are not in direct contact with each other. The second category 
(class 2) is channel hydrates, where the water molecules lie next to other water molecules 
forming channels through the crystals. The third category (class 3) is the ion-associated 
hydrates, in which the metal ions coordinate with the water molecules, and are included 
in the growing lattice structure. Today more than ever before, the ability to develop a 
suitable salt form of a new compound during development and preformulation has to be 
considered. Evaluating the physical properties of potential salt forms is of major 
importance as they may cause changes in dissolution rates and solubility. Changes in the 
hygroscopicity and stability of different salt forms have to be taken into consideration 
during formulation.  
2.2.2 Properties of the dispersion medium 
 
The dispersion medium (i.e. external or continuous phase) is generally a liquid or a 
semisolid. The medium is selected on the basis of safety, density, viscosity, taste and 
stability (Nairn, 1990). Water is the most commonly used medium in pharmaceutical 
suspensions. One factor to consider in the preparation of suspensions is the degree of 
interaction between the internal phase and the dispersion medium. If there is little 
interaction between the internal phase and the dispersion medium, the dispersion is 
lyophobic (or hydrophobic if water is used). The internal phase consists of either organic 
or inorganic compounds and thus has little interaction with the aqueous phase. As a 
result, the suspensions are physically unstable and should be prepared by the methods 
discussed below (section 2.2.3). If there is considerable interaction between the internal 
and external phases, the dispersion is lyophilic (or hydrophilic). In this type of dispersion 
(e.g. gels), the internal phase has polar groups with a hydrophilic character.  
By increasing the viscosity of the dispersion medium, a slower particle sedimentation rate 
can be achieved and thus an increase in stability. The most common method of increasing 
the viscosity is by adding a viscosity enhancer (e.g. natural, semisynthetic, or synthetic 
hydrocolloids, and clays) (Ofner et al., 1989). Ideally, the system should be 
pseudoplastic, i.e., it should have high viscosity during storage and low viscosity during 
shaking.  
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2.2.3 Formulation of a suspension 
 
Since the specific properties of various suspended compounds differ, there is no single 
procedure that will always lead to a successful suspension product; however, certain 
principles are fundamental in all formulations. Suspensions can be prepared either by 
dispersing finely divided powders in an appropriate vehicle or by precipitation.  
 
Dispersion method 
 
The preparation of suspensions by dispersion method consists of three main steps: first it 
is necessary to ensure that the internal phase is of fine particle size, then the internal 
phase is dispersed in the dispersion medium, and finally, the product is stabilised (Nairn, 
1990). Common methods of particle size reduction include e.g. dry milling, spray drying 
and recrystallisation from supercritical fluids (SCF) (Nash, 1988; Mullin, 2001). When 
the dispersion method is utilised for suspension preparation, the vehicle must be 
formulated so that the solid phase is easily wetted and dispersed. Certain solids are 
readily wet by the dispersion medium whereas other are not. The use of surfactants (e.g. 
sodium lauryl sulfate, polysorbates or sorbitan esters) is then desirable to ensure uniform 
wetting of hydrophobic solids as they decrease the solid-liquid interfacial tension, 
because of their dual affinity for both oil and water. Once the particles have been wetted, 
they must be separated and distributed uniformly throughout the liquid vehicle. Sufficient 
agitation of the mixture of solid and liquid must be provided initially to obtain a high 
degree of dispersion (the extent to which particles are separated and distributed 
throughout the vehicle). Sometimes shearing forces from mixers are used to break up 
particle aggregates for better wetting and distribution of the compound. The final step is 
to maintain the stability of the dispersed state. This is mainly done by increasing the 
viscosity of the dispersion medium or by reducing the particle size (see sections 2.2.2 and 
2.2.8). 
 
Precipitation method 
 
The more seldom used method to suspend an insoluble compound is by precipitation 
from a solution. There are several common methods for the production of solids in the 
pharmaceutical industry. Water-insoluble compounds can be precipitated by first 
dissolving them in water-miscible organic solvents and subsequently adding water under 
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standard conditions. The technique where changing the pH causes the precipitation is 
only applicable to those compounds in which solubility is dependent on the pH value. 
When a solution contains a solute (solid e.g. drug) at the limit of its solubility at any 
given temperature and pressure, it is said to be saturated. If the saturation limit is 
exceeded, the solution is supersaturated. Supersaturation is the thermodynamic driving 
force for both crystal nucleation and growth. A supersaturated solution can also be 
achieved by evaporating, cooling or heating the solution or by adding a precipitant 
(Boistelle and Astier, 1988).  
In Fig. 5, point A shows the zone where the solution is undersaturated and any crystals 
present in the system would dissolve. When the concentration increases at a constant 
temperature, the solution reaches the saturation point B. At concentrations greater than B, 
the solution is supersaturated. 
 
 
 
 
 
 
 
 
 
 
  Figure 5. The solubility/supersolubility diagram. 
 
Nucleation (see section 2.2.4) will, however, not occur until the concentration reaches 
point C, which defines what is called the metastable limit. The metastable region (cm-c* 
or Tm-T*) varies from one substance to another and also within one substance because of 
impurities.  
2.2.4 Crystal nucleation 
 
Primary nucleation 
 
Nucleation is the process that precedes crystallisation. Within this process, a nucleus, 
onto which a crystal can grow, develops. If a solution does not contain any solid foreign 
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particle or any roughness of the walls of its container, nuclei can be formed by 
homogeneous type (Myerson and Ginde, 1993). In primary homogeneous nucleation, the 
molecules randomly collide with each other forming small aggregates (Boistelle and 
Astier, 1988). The formation of the aggregates continues up to a critical size above which 
the nuclei transform into crystals.  
Most primary nucleation is of the heterogeneous 
type as it is almost impossible to remove foreign 
bodies completely from crystallising systems. 
Still homogeneous nucleation does form the 
basis of several nucleation theories (Myerson 
and Ginde, 1993; Mullin, 2001). Heterogeneous 
nucleation takes place on foreign surfaces, e.g. 
on the walls of the crystallisation vessel, on the 
surface of the stirrer or any other added seed 
crystal, or on dust present in the solution 
(Boistelle and Astier, 1988). The presence of 
foreign substrates catalyses the nucleation and can induce nucleation at a lower 
supersaturation.  
 
Secondary nucleation 
 
All nucleation that occurs after primary nucleation is called secondary nucleation. When 
crystals of the solute are present or deliberately added, nucleation occurs at a 
supersaturation lower than the one needed for primary nucleation (Mullin, 2001). 
Secondary nucleation can occur through several different mechanisms (Davey and 
Garside, 2000; Myerson and Ginde, 1993). The most common mechanism of secondary 
nucleation, contact nucleation, can result from a disturbance occurring on the surface of a 
growing crystal. Possible contact sources are the crystalliser, impeller or another crystal. 
Collision or attrition breeding results from crystal fragments that serve as nucleation 
sites. The collision breeding is dependent on e.g. crystal hardness (Myerson and Ginde, 
1993). In initial or dust breeding, the secondary nuclei originate from the seed crystals. 
Small crystallites are formed on the seed crystal surface and when placed into solution 
the crystallites become new centres for growth (Myerson and Ginde, 1993; Davey and 
Figure 6. Classification of types of nucleation 
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Garside, 2000). At a high level of supersaturation crystals are needle-like. They are often 
fragile and may break into small parts. These crystal fragments serve as nucleation sites 
and the process is called needle breeding. Shear nucleation has also been presented as 
one mechanism of secondary nucleation, when shear forces due to solution flowing past 
crystals may cause crystal breakage and produce secondary nuclei on the surface (Davey 
and Garside, 2000). 
2.2.5 Crystal growth  
 
When stable nuclei, i.e. particles larger than the critical size, have been formed, they 
begin to grow into crystals of visible size (Mullin, 2001). When a growth unit reaches the 
crystal surface, it either integrates into the lattice or returns to the fluid phase. The ability 
of a surface to capture arriving growth units is dependent upon e.g. the structure, bonds 
and defects (Garside, 1984; Boistelle and Astier, 1998; Davey and Garside, 2000).  
There are several possible pathways by which a molecule passes from the solution to 
become integrated into lattice position on a growing-phase crystal. Crystals are thought to 
grow in a layer-by-layer fashion. Fig. 7 shows the three possible sites for the molecule to 
incorporate into the crystal surface. At site A, the molecule is only attached to the surface 
of a growing layer (flat), at site B, the molecule is attached to both the surface and the 
growing layer (stepped), while at site C, the molecule is attached at three surfaces 
(kinked). Molecules tend to bond at locations where they have the maximum number of 
nearest neighbours as these are the most energetically favourable sites (Myerson and 
Ginde, 1993). The growth units are believed to adsorb onto the crystal surface (A) 
followed by diffusion along the surface to a step site (B), and then further diffused to a 
kink (C), where the incorporation takes place (Mullin, 2001; Myerson and Ginde, 1993).  
 
 
 
 
 
     
  
 
          Figure 7. Kossel´s model of a growing crystal surface 
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When the surface of a crystal is rough there are many potential kink sites, and new 
growth units arriving at the surface will find a growth site (Fig. 8) (Garside, 1984). The 
crystal growth is therefore continuous. On the other hand, when the interface is smooth, 
growth is more difficult. If the growth units do not find a growth site, they either return to 
the liquid phase or form two-dimensional circular clusters on a flat surface (Fig. 8)  
(Davey and Garside, 2000). These islands act as new kink sites where additional growth 
units can join the surface. When a complete layer has been formed, the crystal has grown 
by one monolayer (Boistelle and Astier, 1988). 
Crystal growth like this is referred to as two-
dimensional growth or surface nucleation. 
Two-dimensional growth can be mononuclear 
when there is only one cluster which spreads 
across the surface at the same time. In the 
polynuclear model several clusters 
simultaneously spread on the crystal surface. 
In contrast to the mononuclear growth where the 
whole crystal surface is covered before the next cluster is formed, this model allows 
several layers to grow at the same time.  
Most crystals contain imperfections (see section 2.2.6); most commonly screw 
dislocations, providing one or more steps which can spread over the surface (Boistelle 
and Astier, 1988; Myerson and Ginde, 1993). Molecules absorb on the crystal surface and 
diffuse to the top step of the dislocation and the surface becomes a spiral staircase. When 
one layer is complete, the dislocation still exists and the spiral growth can continue. 
Growth can continue to a certain maximum determined by the supersaturation in the 
medium in which the crystal is growing (Mullin, 2001). 
2.2.6 Imperfections in crystals 
 
In a crystal, each atom or molecule has a precise location, forming a continuous structure 
(Mullin, 2001). If the structure is disrupted in any way, the crystal is said to have 
imperfections. Crystals are always imperfect in some sense, and although the defects 
usually are small, they might have an impact on some important chemical and physical 
factors, e.g. dissolution, solubility, and melting point (Burt and Mitchell, 1981). The 
defects in organic crystals can be divided into point, line and surface defects. 
Figure 8. Two-dimensional crystal 
growth on a flat site. 
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Dislocation line
Point defects  
 
A point defect is a defect that occurs at a 
specific lattice point. The most common point 
defects are presented in Fig. 9. Vacancies are 
lattice sites from which units are missing 
(Myerson and Ginde, 1993; Mullin, 2001). 
The missing units may be atoms, molecules or 
ions. A foreign unit occupying positions 
between the regular lattice sites of the crystals is 
called interstitial impurity. When a foreign unit occupies a regular lattice site, taking the 
place of the host atom, it is a so-called substitutional impurity. These defects are called 
point units, as they involve a single unit of the crystal structure.  
 
Line defects (dislocations) 
 
Line defects are defects that extend through the 
crystal along a one-dimensional boundary, such as 
a line or a curve. These defects are formed when 
planes of atoms are out of place. The two main 
types of line defects are the edge and screw 
dislocations (Mullin, 2001). An edge 
dislocation is illustrated in Fig. 10. The figure 
shows that half of the vertical row of atoms is missing. The position of the dislocation is 
marked by an arrow. The lattice points are displaced in the region of the dislocation but 
get smaller and finally return to normal. The other type of line defect is the screw 
dislocation. In screw dislocations, atoms have moved one lattice unit higher at the edge 
forming a cotinuous spiral-formed step. Without dislocation, the movement of atoms 
relative to each other would be very difficult, and no plastic deformation would be 
possible. The enormous number of dislocations is also the reason why metallic parts bend 
during manufacturing. Ceramic materials, for exmple, are brittle as they do not contain as 
many dislocations.  
 
 
 
 
           Figure 10. Line dislocation 
Vacancy
Interstitial Substitutional
Figure 9. A schematic model of vacancy, 
interstitial and substitutional point defects 
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Surface defects 
 
Surface defects occur wherever the crystalline structure of 
the material is not continuous across a plane. Surface, 
planar, or interfacial defects are divided into crystallite, tilt 
and twist boundaries. These boundaries are formed in 
crystalline materials as the result of mechanical or thermal 
stresses or irregular growth (Mullin, 2001). Crystallite 
boundaries, for example, can be created when the crystalline 
structure does not match perfectly with the crystalline 
structure in the neighboring area (Fig.11). The area between 
these crystalline areas (crystallites) is called a crystallite 
boundary. 
2.2.7 Factors affecting crystal properties 
 
The degree of saturation is the critical parameter controlling the rate of nucleation 
(Myerson and Ginde, 1993). At a high supersaturation, the presence of fragments that 
serve as a source of secondary nuclei, is greater and results in a larger number of nuclei. 
The number of crystals is dependent on the nucleation and thus “one nucleus, one large 
crystal; a billion nuclei, a billion tiny crystals” (Byrn et al, 1999). As the degree of 
saturation increases, the crystal size distribution tends to reduce and additionally the habit 
tends to change towards acicular-shaped (Haleblian, 1975).  
     
When crystal growth takes place in the presence of impurities, the growth rates of the 
crystal can be strongly affected. Impurities, such as ions and surface-active agents, may 
decrease the amount of molecules incorporating onto the crystal surface by selective 
adsorption (Dirksen and Ring, 1991). Impurities may affect the crystal morphology even 
at a very low concentration (ppm), but usually they become more efficient with 
increasing concentration (Davey and Garside, 2000; Mullin 2001). Sometimes impurities 
are deliberately added to achieve the desired crystal morphology.  
 
The cooling of a solution is one of the most widely used methods for achieving the 
supersaturation essential for crystallisation (Jones and Mullin, 1974). At low cooling 
temperatures the crystal size decreases owing to a higher level of supersaturation and an 
Figure 11.  Crystallite boundary 
between two crystalline areas. 
Crystallite Crystallite
Crystallite Boundary
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increase in nucleation rate (Myerson and Ginde, 1993). The cooling rate also affects the 
crystal habit through an effect on the degree of supersaturation. Rapid cooling results in 
needle-shaped or thin plate-shaped crystals.  
 
The crystal size can be altered by varying the stirring rate owing to its influence upon 
nucleation rate (Mackellar et al. 1994). Generally, rapid stirring is said to enhance the 
nucleation rate resulting in smaller crystal size, although this is not always the case 
(Mullin, 2001). In some cases, stirring might also lead to a thinning of the absorbed layer 
(in secondary nucleation), causing fewer fragments and thereby leading to lower 
nucleation rates (Myerson and Ginde, 1993). The rate of stirring must be strong enough 
to provide a complete contact between the crystals and the solvent. When a particular 
stirring rate is reached, it should not be exceeded as this could cause a mechanical 
breakage of the crystals. 
2.2.8 Physical stability of suspensions 
 
Since a suspension exists in more than one state (liquid and solid), it possesses some 
disadvantages relative to other dosage forms. Suspensions are thermodynamically 
unstable systems, i.e. they always tend toward ultimate loss of stability. The primary 
disadvantage is their physical instability, such as the difficulty of redispersability of the 
sediment and crystal growth (Akers et al., 1987). A suspension must remain sufficiently 
homogeneous for at least the period of time necessary to remove and administer the 
required amount after shaking.  
The rate of sedimentation of a suspended phase depends on several factors which may be 
controlled by pharmaceutical manipulation. For example, by reducing the particle size or 
by increasing the viscosity and density of the dispersion medium (see sections 2.2.2 and 
2.2.8), the rate of sedimentation can be retarded. Even though the particle size of a 
compound is small when the suspension is first prepared, a certain degree of crystal 
growth always occurs during storage. Over a period of time the small crystals will 
diminish further, whereas the larger particles will increase in size, owing to a difference 
in solubility rates of particles of different sizes (Ostwalt ripening). A number of additives 
such as polymers and surfactants have been suggested to prevent crystal growth (Motawi 
et al., 1982). A change from one pseudopolymorphic form to a thermodynamically more 
stable crystal form, or a change in the crystal habit due to the degree of hydration of the 
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compound may lead to crystal growth in the suspensions. This may cause caking and 
deflocculation of the suspension (Khankari and Grant, 1995). The effect of temperature 
changes is important when measuring physical stability as it might affect both the 
solubility and the recrystallisation of the suspended compound. Chemical and microbial 
stability factors are also relevant when studying the stability of suspensions.  
2.2.9 Methods for analysing suspensions 
 
Microscopy 
 
Optical microscopy is the only technique by which it is possible to achieve information 
about both the morphology and size distribution of the crystals under study (Brittain, 
1999). This widely used method is an important tool for characterising different 
polymorphs and pseudopolymorphs as the crystal habit usually changes with the 
structure.  The magnification of an optical microscope is usually not beyond 600x, which 
might limit its use when observing microcrystalline materials. When a higher 
magnification level is needed, the electron microscope can be used as a complementary 
method on account of its very high level of magnification (90 000x).   
 
Structure of the solid material 
 
X-ray powder diffraction (XRPD) has been used in two main areas, for the fingerprint 
characterisation of crystalline materials and the determination of polymorphs (Cullity, 
1978). 
Fig. 12 illustrates the principle of x-ray 
diffraction technique which is based on 
Bragg’s law. This describes the diffraction of 
monochromatic x-ray radiation impinging on 
a plane of atoms. The two paths, A and B for 
the incident and diffracted beams, differ in 
length by nλ = 2d sin θ where d is the distance 
between atomic layers in a crystal and θ the 
angle of beam diffraction. The variable lambda (λ) is the wavelength of the incident x-ray 
beam, and n is the order of the diffraction pattern. Quantitative determination of the 
Figure 12. Schematic diagram for  
determining Bragg’s law 
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estimated amount of different polymorphs can be difficult due to preferred orientation. 
Preferred orientation can be defined as a condition where the distribution of crystal 
orientation is non-random (Cullity, 1978). The changes in the intensity of the diffraction 
maximum can be explained by this. Needle-shaped and plate-like particles are prone to 
preferred orientation. Yet these effects can be minimised by reducing the particle size 
(Byrn et al., 1999). The presence of overlapping reflections can also make the 
determination of intensity more difficult (Agatonovic-Kustrin et al., 1999). XRPD has 
also been used to quantify sample crystallinity, even though no clearly defined diffraction 
peaks can be recorded with amorphous materials. 
 
Near-infrared (NIR) was discovered in 1800 as the first non-visible region in the 
absorption spectra (Blanco et al., 1998). Near-infrared spectroscopy covers the 
electromagnetic spectrum from 760 to 2600 nm. Like the other vibrational spectroscopy 
methods, NIR spectroscopy measures stretchings and bending of bonds between atoms. 
All organic bonds have absorption bands in the NIR region but the method is particularly 
used for quantitative measurements of O-H, N-H, and C=O bonds. NIR spectroscopy is 
widely used for quantification of water and it can also be used to examine the state of 
water. The most intense absorption bands of pure water in the NIR region are found 
around 1450 and 1940 nm (Osborne et al., 1993). NIR spectroscopy offers a number of 
important advantages, being a fast, non-destructive method of high precision that requires 
minimal sample preparation. Raw data often needs to be mathematically processed before 
removed in the spectra. The first and the second derivatives are most commonly used.  
 
Thermal methods  
 
By using a hot stage on the microscope, any changes in a solid can be related to 
temperature by direct observation (Byrn et al., 1999). Hot stage microscopy with imaging 
facilities is an important supportive tool for the characterisation of melting, desolvation, 
crystallisation and solubility as a function of temperature (Brittain, 1999). Changes in 
crystal morphology during heating may indicate a change from one crystal form to 
another, while a change in the transparency may be caused by dehydration prior to 
melting (Byrn et al., 1999).   
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Differential scanning calorimetry (DSC) is a routinely used thermal analytical technique 
for measuring phase transitions (Giron, 1998; Clas et al., 1999; Bond et al., 2002). DSC is 
used to measure the heat flow into and out of a sample cell with respect to a reference cell 
in a controlled atmosphere and over a wide temperature range (Byrn et al., 1999; Giron, 
1998). The result of a DSC analysis is a thermogram, where the endotherms represent 
processes in which heat is absorbed (e.g. desolvation, melting, and phase transitions) 
(Brittain, 1999). The exotherms represent processes where energy is released, such as 
crystallisation. This method together with thermogravimetric analysis (TGA) is 
particularly useful in the study of hydrates with dehydration steps at low temperatures 
(Giron, 1995).  
In TGA, the measured parameter is the weight loss of the material as a function of the 
applied temperature (Brittain 1998). This may involve controlled heating or cooling or a 
maintained constant temperature. The TGA is most commonly used to study the 
desolvation processes of hydrates and other solvates and can be used as an adjunct to 
Karl-Fisher titrations for the determination of moisture.  
 
Rheology and mechanical properties 
 
Rheology is used to define the consistency and can be described by viscosity (thickness) 
and elasticity (stickiness) of a product (Blomstedt, 2000). Rheology is a viscosity 
measurement by which it is possible to characterise the flow behaviour and determine the 
structure of a material. Gases and liquids are usually described as viscous fluids and 
solids as elastic materials. Several materials (e.g. food products) show both viscous and 
elastic properties (i.e. viscoelastic), as they are able to store some of the deformation 
energy while some of it is lost. The main types of viscometers are rotational and 
capillary. The cone-plate viscometer, an example of a rotational viscometer, consists of a 
flat circular plate with a wide-angle cone placed centrally above it. The cone just touches 
the plate and the sample is loaded into the gap.  
Dynamic mechanical analysis (DMA) supplies information about the viscoelastic 
properties of pharmaceutical and biomedical systems (Menard, 1999; Jones, 1999). It 
enables the measurement of the viscosity of the material during applied force and 
stiffness (modulus) from the sample recovery (Menard, 1999). These properties are often 
described as the ability to lose energy as heat and the ability to recover from deformation. 
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DMA is a versatile technique that may be used to simultaneously characterise both 
rheological and thermal properties of a wide range of sample types (Jones, 1999). 
Dynamic mechanical testing methods have been widely used in the characterization of 
viscoelastic materials, particularly in the polymer sciences (Craig and Johnson, 1995; 
Giron, 1998).  
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3 AIMS OF THE STUDY 
 
The unpleasant gritty texture of phytosterols and the poor solubility in oil or water has 
caused several problems in their preparation and administration. In the present study, a 
non-esterified phytosterol suspension in oil was prepared for oral administration. To 
avoid the gritty sensation in the mouth, the preparation of this suspension was optimised 
in order to achieve a microcrystalline particle size. As this phytosterol suspension is 
intended for addition into cholesterol-lowering food and pharmaceutical products, the 
knowledge of its thermal changes during process is of importance as well as the physical 
stability during storage. A clinical test performed earlier using a similar microcrystalline 
suspension revealed a significant reduction of cholesterol levels. A dynamic in vitro study 
has been performed to understand the mechanism by which phytosterols interfere with 
cholesterol absorption. 
 
 
The specific aims were  
 
- to prepare a microcrystalline phytosterol suspension in oil by precipitation method 
and to describe how different processing parameters affect crystal properties of 
phytosterol, 
- to investigate the different pseudopolymorphic forms of phytosterol in the 
presence and absence of water,  
- to evaluate physical properties of the microcrystalline suspension during storage 
and to characterise the changes that occurred during heating, and 
- to study the effects of the microcrystalline phytosterol suspension on cholesterol 
solubilisation in vitro, and to compare the effect of medium and long chain length 
lipid on the solubilisation. 
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4 EXPERIMENTAL 
 
A more detailed description of the materials and methods is given in the respective 
original publications (I-V). 
 
4.1 Materials 
 
β-sitosterol (β-sitosterol for biochemistry) was purchased from Merck, Germany (I,V), 
DRT (Les Dérivés Résiniques et Terpéniques), France (II,III) and from Calbiochem 
(Biosciences Inc., La Jolla, USA) (IV). According to our GC-MS analyses, the 
phytosterol from Merck contained 79% pure β-sitosterol (14% β-sitostanol, 6% 
campesterol and 2% campestanol). The wood-based phytosterol from DRT contained 
≥78.5% β-sitosterol (10% β-sitostanol, 8.7% campesterol and campestanol 1%) and the 
Calbiochem phytosterol with 75.5% pure β-sitosterol (13.0% β-sitostanol). The 
cholesterol was a Sigma Chemical Co. (St. Louis, USA) product (V). According to the 
GC-MS analyses the cholesterol was 99% pure.  
The MCT oil (medium chain triglyceride) was from SHS International Ltd., UK (I-IV). 
The purified MCT oil that was used contained mainly caprylic and capric acid-based 
triglycerides. The other oils used were soybean oil (LCT; ≥ 85% linoleic, oleic and 
linolenic acid), which was a Sigma product and Captex 355 (MCT; ≥ 95% caprylic and 
capric acid) a product from Abitech Corporation (Janesville, USA) (V). Polyoxyethylene 
20 sorbitan mono-oleate (polysorbate 80), (Tween 80® for parenteral use, ICI Surfactant, 
Germany) was added when studying the effect of surfactant on the crystal size 
distribution (III). 
4.2 Preparation of phytosterol crystals (I) 
 
Anhydrous phytosterol was prepared by crystallising the sterol from supersaturated 
acetone and hydrated from crystals from acetone-water 95:5 (v/v) mixture. Anhydrous 
crystals were dried over night at 80 °C and stored over silica gel at 20±2 °C. Hydrated 
phytosterol was stored over a saturated solution of K2SO4 at 20±2 °C, which 
corresponded to 98% relative humidity. 
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4.3 Preparation of the suspensions (I-V) 
 
The suspensions were prepared by heating phytosterol or cholesterol and oil (MCT, 
Captex 355 or Soybean oil) in a vessel while stirring. Phytosterol/cholesterol was 
dissolved at about 100 °C and a clear solution was formed. 
Suspensions were prepared by heating the phytosterol (I-IV) or cholesterol (V) in 
medium chain triglyceride (I-IV) oil or long chain triglyceride (V) up to 100-110 °C until 
a clear solution was formed. During cooling, at about 90 °C, purified water of the same 
temperature was added. The suspension was stirred until it reached room temperature (I-
III). Additionally, the suspensions were prepared by rapid cooling (II-V) in order to 
achieve a smaller crystal size. The first part of the process was the same as explained 
earlier. However, following the addition of water (90°C) to the clear solution, in this case, 
the vessel was then immediately immersed in ice. The suspension was subsequently 
stirred until it reached room temperature (+25 °C). After preparation the samples were 
kept at room temperature for half an hour. The samples were then stored in airtight plastic 
containers at +4 °C (I-V) and -19 °C (II). Compositions of the sterol suspensions are 
presented in Table 2. 
 
Table 2. Compositions of the studied suspensions in publications I-V.  
The proportions of phytosterol: oil: water (w/w). 
I II III IV V 
20:80:00 05:90:05 17:70:13 05:82:13 17:70:13 
20:80:01 05:75:20  17:70:13  
20:80:05 17:78:05  17:83:00 17:83* 
20:80:10 17:63:20  30:57:13  
20:80:15 30:65:05    
10:80:05 30:50:20    
05:80:05     
* Cholesterol: MCT/LCT 
 
When studying the effect of surface-active agent on the crystal size, polyoxyethylene 20 
sorbitan mono-oleate (polysorbate 80), was added to the water before combining the 
water and phytosterol-oil mixture (III). Batches with surface-active agent contained 1% 
(w/w) polysorbate 80. The effect of cooling temperature was studied by immersing the 
vessel in which the suspensions were made in an ice/water bath at six different levels of 
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temperatures: 0°C, 10°C, 20°C, 30°C, 40 °C and 50 °C (±2 °C). The cooling temperature 
was measured every 30 seconds for four minutes. By this time the suspensions immersed 
in either 0 °C or 10 °C had reached at least room temperature. To investigate the effects 
of stirring time and stirring rate, the batches were prepared with a mixer (Kenwood Chef 
Classic KM 400, Great Britain). The metallic bowl was covered with a frozen shell to 
cool down the suspension in the same way as was done when immersing the beaker in 
ice. The rotation speed of the mixer was 0, 60, 120, 200 and 250 rpm. Stirring time was, 
in this case, 3 minutes. At this point the mass had reached room temperature and visually 
the system was equally well agitated. Every 30 seconds the bowl was cleaned on the sides 
with a spatula. The effect of stirring time was studied at 250 rpm at the following times: 
30, 60, 120, 240 and 360 s. In these cases also, the bowl was cleaned on its sides every 30 
seconds. 
4.4 Analysis of phytosterol crystals and suspensions 
 
Optical Microscopy (I-IV) 
 
The size distribution and the habit of the crystals were evaluated by optical microscopy 
(Leica DMLB, Leica Mikroskopie und Systeme GmbH, Germany). The samples were 
prepared by taking a small amount of the suspension and diluting it with a small amount 
of MCT oil, because of the high viscosity. The crystal size of 300 particles per sample 
was measured manually using a measuring rod. Observations regarding crystal habit 
during storage were made on a visual basis (II). Crystal size and habit determinations 
were carried out on the samples stored at +4°C, initially, and after 1, 2, 4, 8, 12 and 16 
weeks of storage. Samples stored at -19 °C were determined initially and after 12 weeks 
of storage.  
 
X-Ray Powder Diffraction (XRPD) (I-IV) 
 
The crystal structure of the phytosterol suspensions was measured using an x-ray powder 
diffractometry (XRPD) with a theta-theta diffractometer (Bruker AXS, D8 Advance, 
Germany) in a symmetrical reflection mode with Cu Kα radiation (1.54 Å) using Göbel 
mirror bent gradient multilayer optics. The scattered intensities were measured with a 
scintillation counter. The angular range was from 3° to 30° using a step size of 0.05° and 
the measuring time was 1s/increment. The x-ray diffraction measurements for the thermal 
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analyses were made as described although each sample was measured at several 
temperatures (VT-XRPD) between 25 and 60 °C (IV).  
 
Differential scanning calorimetry (DSC)(IV) 
 
A differential scanning calorimeter (Mettler DSC30 with TC15 TA processor, Mettler-
Toledo AG, Switzerland) was used in the study. The analyses were made by STARe 
Thermal Analysis System version 3.1 (Mettler-Toledo-AG). The DSC was calibrated 
using the melting temperature of n-pentane, n-hexane, mercury, ion changed water, 
gallium and indium. In addition, the melting point of indium was checked once during the 
determinations. Each sample was first heated from 25 to 60 °C/min. This was followed 
by cooling down to 25 °C and heating back to 60 °C, 5 °C/min. The samples (10-30 mg) 
were hermetically sealed in 40 µl aluminium pans (n≥2; analysed the day after 
preparation). An empty aluminium pan was used as reference sample.  
 
Dynamic mechanical analysis (DMA) (IV)  
 
A dynamic-mechanical analyzer (DMA 242, Netzsch-Gerätebau GmbH, Selb, Germany) 
was used to observe the storage modulus, loss modulus and tan δ as a function of 
temperature. The DMA was equipped with a DMA 242 measuring unit, a cooling gas 
controller, a DMA 242 and TASC 414/3 controller, and Netzsch DMA 242 software 
version 1.5.  The instrument was used with a disk-bending sample holder. The sample 
holder consisted of three stainless steel layers with circular holes of 30 and 26 mm in 
diameter. The layers were separated by two 0.05 mm thin PET plastic films and the 
sample was located between these two films. During the analysis, sinusoidally varying 
stress was applied to the material observed as a function of temperature. The samples 
were analysed on the day after preparation, at frequencies of 0.1, 0.5, 1, 2.5 and 5 Hz and 
the amplitude was 7.5 µm. The samples were heated at a heating rate of 2 °C/min from 30 
°C to 60 °C. These analyses were used to obtain three major parameters: (1) the storage 
modulus, G′, which measured the amount of energy stored in the material during 
deformation; (2) the loss modulus, G′′, which is proportional to the amount of energy 
dissipated per cycle; and (3) the loss tan δ, which corresponds to the ratio of energy 
stored per cycle (Menard, 1999). 
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Thermogravimetric (TG) analysis (I) 
 
The thermogravimetric (TG) analyses of the crystalline phytosterol samples were 
performed with a Mettler TGA/SDTA analyzer (model 851e, Mettler Toledo, 
Switzerland). Samples (5 mg) were analysed in open aluminium pans under nitrogen flow 
(50 ml/ min) at 25-150 °C with a heating rate of 10 °C/min. The temperature scale of the 
equipment was calibrated with zinc and indium, while the microbalance was calibrated 
with calcium carbonate. 
 
Near-infrared spectroscopy (NIR) (I) 
 
Near-infrared (NIR) spectra were measured with a Fourier transform (FT-NIR) 
spectrometer (Bomem MD-160 DX, Hartman&Braun, Quebec, Canada) using Bomem-
GRAMS software (version 4.04, Galactic Industries, Salem, NH, USA). The spectra were 
measured through the bottom of a glass vial containing the sample. FT-NIR spectra of the 
crystals and suspensions were recorded over a range of 4000 and 10 000 cm-1 with a 
resolution of 16 cm-1. Standard reflection was measured using a Teflon background 
(Labsphere, SRS-99-070, North Sutton, NH, USA). The samples were scanned 40 times, 
and each spectrum was reported as the average of these scans.  
 
Cone and plate rheometer (I, II) 
 
The viscosity of the suspensions was measured, as a function of shear rate, with a cone 
and plate rheometer (CP 5/30, Bohlin VOR Rheometer, Bohlin Reologi, Sweden). The 
gap between the lower and the upper plate was 0.5 mm. The measuring temperature was 
20°C. 
 
Karl Fisher Analysis (I, III) 
 
The water content of the phytosterol starting material was determined by Karl Fisher 
titrimetry (Mettler DL35, Mettler-Toledo, Switzerland). Hydranal®- Titrant 2 (Sigma, 
USA) was used as the titer and Hydranal® Solvent CM (Sigma, USA) as the solvent.  
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4.5 Dynamic in vitro lipolysis method (V) 
 
In vitro lipolysis 
 
In in vitro lipolysis, a pH-stat continuously titrates the fatty acids that are liberated via 
lipolysis. The lipolysis is carried out in a reaction medium with a low buffering capacity, 
thereby ensuring that fatty acids liberation causes the pH to drop. The number of moles of 
neutralising hydroxyl ions present in this volume of titrant is parallel to the fatty acid 
liberation caused by lipolysis (MacGregor et al., 1997).  
The in vitro lipolysis experiments were performed in accordance to the previous studies 
described earlier by Professor Charman and his team (Sek et al., 2001; Sek et al., 2002; 
Kaukonen et al., 2004a; Kaukonen et al., 2004b). Cholesterol and/or phytosterol 
suspensions were dispersed in 9 mL of bile salts (BS)/phospholipids (PL) and mixed 
micelles prepared in a pH 7.5 buffer. All digests contained a total of 50 mg of LCT or 
MCT, i.e. 25 mg of pure triglyceride was added when only cholesterol or phytosterol 
suspensions were studied. Two levels of BS/PL concentrations were used to represent fed 
or fasted state small intestinal conditions. The amount of phytosterol contained in the 
dose of suspension was either 14 µmol or 28 µmol while the amount of cholesterol was 
15 µmol. Cholesterol-loaded micelles with 1.5 mM cholesterol were also used to simulate 
the presence of endogenous or pre-solubilised cholesterol under fed state conditions. 
Lipolysis experiments were performed at 37°C in a stirred and thermostatted glass vessel 
and initiated by the addition of 1 mL of 20% pancreatin suspension. The pancreatin 
extract contained 10 000 TBU/ml of pancreatic lipase conferring physiologically relevant 
lipase activity. The lipolysis was performed over 60 min using a pH-stat titration unit 
(Radiometer, Copenhagen, Denmark) which maintained the pH at 7.5. The fatty acids 
produced by triglyceride lipolysis were titrated with 0.2 M NaOH. At the end of each 
experiment a lipolysis inhibitor was added to the digestion mixture to stop further 
digestion. Two 4 mL aliquots of the post-digestion mixtures were then ultracentrifugated 
in order to separate the digests into an oil phase, an aqueous phase, and a precipitated 
pellet. The aqueous phase was aspirated into a syringe by penetrating the side of the tube 
and transferred into glass vials. Finally, the samples were dried overnight in a 
lyophilisator (HETO LyoPro 3000, Freeze dryer) prior to analysis by gas chromatography 
(GC, Agilent technologies 6890N Network GC with a RTX®-5w/INTEGRA fused silica 
column).  
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Solubility determination 
 
The equilibrium solubility of phytosterol was determined by adding anhydrous 
phytosterol crystals (dried over night at 80 °C, 0% RH) into the aqueous phase obtained 
after in vitro lipolysis of 50 mg of LCT or MCT in fed state micelles pre-loaded with 1.5 
mM cholesterol. A total of four lipolyses were performed (both for MCT and LCT) 
whereafter the aqueous phase was separated by ultracentrifugation. Solid phytosterol was 
added, after which the samples were incubated at +37 °C for the entire period of the 
solubility studies and vortexed periodically. Sterol concentrations were analyzed from 
samples taken at the start of the experiment and after 6, 24, 48, and 120 hours of 
incubation by GC. The samples were filtrated prior to determination and the filtrate was 
collected for analysis. In order to assess the potential loss of solubilised sterol by 
filtration, aqueous phase samples from digests containing both cholesterol and 
phytosterols were analysed prior to and after filtration. The loss of sterols was ≤ 1.7%. 
No apparent visual changes were observed during the solubility study. 
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5 RESULTS AND DISCUSSION 
5.1 Crystal forms of phytosterol (I-IV)  
 
Phytosterol was observed to exist in three different crystal forms; anhydrous, 
hemihydrate and monohydrate crystals (I). When phytosterol was crystallised in the 
absence of water from acetone, anhydrous flaky-like sterol crystals were formed (I, Fig. 
6a). In the presence of water phytosterol precipitated from acetone-water as needle-
shaped monohydrate crystals (I, Fig. 6c-d). This crystal form is unstable and a more 
stable hemihydrated phytosterol was formed when approximately half of the water left 
the monohydrated structure. The main x-ray reflections of the three pseudopolymorphic 
forms are presented in Table 3.  
 
Table 3. The main x-ray reflections of the three different pseudopolymorphic forms of phytosterol (I) 
Crystal form (Å)           
Anhydrous 17.6 11.7 8.8 7.07 5.87 5.23 3.92     
Hemihydrated 18.8 12.4 7.45 6.22 5.90 5.70 5.32 5.05 4.81 4.74 4.61 
Monohydrated 17.6 11.7 7.05 5.86 5.03 4.81 4.56 3.92    
 
 
Phytosterol crystal forms in oil suspensions 
 
The formation of phytosterol crystal structure in oil suspension is dependent on the water 
content (I, Fig. 8). When anhydrous phytosterol was used, oil suspensions without added 
water produced x-ray reflections that corresponded well to those of anhydrous 
phytosterol. However, if phytosterol was used as received and no water was added, the 
crystal form was mostly anhydrous but reflections corresponding to a hydrated 
phytosterol crystal form were also apparent (IV, Fig.2). When the added amount of water 
was 1%, both the hemihydrated and monohydrated crystal forms were observed (I, Fig. 
8). As the amount of water was beyond 5%, the x-ray diffraction patterns showed that the 
monohydrated form was in majority (I,IV).  
Further analysis indicated that the amount of phytosterol, in addition to the water content, 
can affect the crystal structure (II). When the suspension contained less sterol (5%), the 
monohydrated phytosterol was in majority, but as the sterol concentration increased 
(30%), so did the hemihydrated crystal form. This implies the possibility of an increased 
penetration of water into the crystals when sterol content was low. The suspension that 
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contained 5% sterol was mostly amorphous, from the large amount of oil, and thus the 
estimation was difficult.  
Different preparation methods (i.e. changes in temperature, stirring, addition of a surface-
active agent) were observed not to affect the crystal structure of phytosterol in oil-water-
suspensions (III). Despite the preparation, the diffraction patterns of the suspensions 
included reflections of both hemihydrated and monohydrated forms indicating that the 
suspensions contained a mixture of both crystal forms.  
 
Stability of phytosterol crystal forms 
 
The sterol crystal forms, containing different amounts of phytosterol, were stable in 
suspensions during a storage period of 16 weeks in +4 °C and in -19 °C (II). Since the 
suspensions contained water (5%), the initial crystal form was a mixture of hemihydrate 
and monohydrate forms. A minor increase of the monohydrate form was observed, 
although an accurate quantitative determination of different phytosterol crystal forms in 
suspensions is difficult because of preferred orientation and due to the presence of some 
overlapping reflections. 
However, the degree of crystallinity changed during the storage period and caused a 
typical sigmoid-shaped curve (II, Fig. 7) (Avrami, 1939). The amorphous form increased 
during the first four weeks whereafter it began to decrease and the degree of crystallinity 
returned to the initial level in twelve weeks. During the last four weeks, some decrease in 
the degree of crystallinity was observed again. An increase in oil content reduced the 
amount of crystalline form while water content had no effect. A clear increase in the 
degree of crystallinity was observed with growing phytosterol concentrations.  
 
5.2 Dehydration from phytosterol  
5.2.1 Dehydration from hydrated phytosterol crystals (I) 
 
Thermal analysis (DSC, TG) of phytosterol crystals showed that the dehydration of 
monohydrated phytosterol was a two-step process. The monohydrated form contained 
approximately 1 mol water/mol phytosterol, while the dehydration to the hemihydrated 
form reduced the amount to 0.5 mol water/mol phytosterol. The evaluation of the 
phytosterol crystals using near-infrared (NIR) reflectance spectroscopy revealed the 
presence of two different energy states of water in the spectra of the different 
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pseudopolymorphs (I, Fig. 4). The less tightly bound water (absorbance maxima at 1901 
nm) of the monohydrate form dehydrated at temperatures below 60 °C and a 
hemihydrated structure was formed. The more tightly bound water (absorbance maxima 
at 1949 nm), which appeared both in monohydrate and the more stable hemihydrate 
structure, dehydrated after further being heated up to 90 °C. The early onset of 
dehydration during heating is characteristic of channel hydrate dehydration (Morris and 
Rodrigues-Hornedo, 1992). The explanation for the ease with which phytosterol 
dehydrates is the migration of the water molecules along tunnels where they lie 
(Vippagunta et al., 2001).  
5.2.2 Dehydration from phytosterol crystals in oil suspensions (IV) 
 
The dehydration of phytosterol crystals in oil suspensions was studied at temperatures 
from 25 to 60 °C. The main changes in the suspensions were detected around 40 °C. In 
accordance to the previous section (4.2.1) the water molecules were weakly bonded to 
phytosterol, as the dehydration from monohydrate to hemihydrate crystal form occurred 
at such low temperatures. The somewhat earlier onset of dehydration compared to plain 
crystals is explained by the surrounding oily vehicle and the crystal size distribution, 
which in this study was considerable smaller. The broad endotherms, resulting from the 
DSC measurements (IV, Fig. 3), are typical for crystals with weakly bonded water 
molecules and strengthen the assumption of channel hydrates (Morris and Rodrigues-
Hornedo, 1992). At the end of the study, at 60 °C, the dehydration process was not 
completed, since there were still both mono- and hemihydrated crystal forms left. Further 
heating was, however, impossible due to rapid dissolution of the crystals. With the DMA 
it was possible to follow the dehydration from a rheological point of view. At increasing 
temperatures the dehydrated water molecules were immiscible in the surrounding oil 
phase and acted as a lubricant between the solid phase and the oil phase (IV, Fig. 4). In 
addition to dehydration, an increase in temperature caused the dissolution of the smallest 
phytosterol crystals and larger crystals were formed at the expense of the smaller ones 
(Ostwald ripening). This was recognised as increased elasticity in terms of DMA 
measurements and as a growth in the intensities of some reflections during x-ray 
measurements (IV, Fig. 2). At temperatures beyond 50 °C, even the larger crystals started 
to dissolve, and the suspension became less elastic again. Due to the dissolution of the 
crystals, the x-ray reflections also started to diminish. As the water was immiscible in the 
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surrounding oil phase, the water molecules were available for phytosterol crystals during 
cooling. The DSC results suggested a reversible dehydration process.  
5.3 Crystal habit and size distribution of phytosterol 
 
For poorly soluble compounds, particle size distribution is one of the most important 
factors which affects bioavailability in relation to the physicochemical properties of a 
compound. Thus the large differences in the phytosterol crystal length and the habit 
modification produced by various process parameters are likely to have an effect on 
bioavailability of the suspension. The use of phytosterols in functional foods has faced 
several problems since phytosterols have an unpleasant texture. To avoid the gritty 
sensation in the mouth, a microcrystalline particle size is desirable. The optimum particle 
size for a so-called creamy product lies between 10 µm and 50 µm (Tyle, 1993; Viaene 
and Januszewska, 1999; Kilgast and Clegg, 2002). The crystal size is of greater 
significance if the crystal habit is hard and sharp than if it is flat and rounded. Crystal can 
be even up to 80 µm, if the habit is soft, and still have a creamy oral texture. 
Additionally, small crystals have a high free surface area, which facilitates the saturation 
of the sterol solubility in the intestinal lumen and interference with cholesterol 
absorption. 
5.3.1 The effect of the composition on crystal modifications (I,II) 
 
Phytosterols are practically insoluble in water and the solubility in MCT-oil was between 
3.5-4.0% (w/w) and 1.5-2.0% (w/w) when water was present (I). Due to the low 
solubility in oil or a mixture of oil and water, β-sitosterol was saturated in all the studied 
compositions. The phytosterol crystal appearance in oil suspensions was affected by the 
presence of water in the suspension (I). The absence of water resulted in large platy-like 
particles (I, Fig. 6a). When the water content was between 5 and 20%, the crystals were 
acicular (I, Fig 6c-e and II). Crystal length varied according to the concentration of the 
sterol. The length of the acicular-shaped crystals in the water-containing oil suspensions 
decreased with an increasing phytosterol concentration (I, Fig. 7 and II Fig. 2). A high 
sterol concentration resulted in high supersaturation and thus the formation of small 
crystals. At a high level of supersaturation the needle-shaped crystals can be fragile and 
break into small parts (Myerson and Ginde, 1993). These parts act as secondary nuclei 
onto which molecules can attach and new crystals can be formed.   
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It is thought that adsorption of an impurity onto the crystal surface most likely has an 
inhibitory effect on crystal growth. The addition of a surface-active agent (Polysorbate 
80) in the suspension did, however, only have a minor effect on the phytosterol crystal 
growth (III). The crystal length was reduced only if the crystals were larger, due to the 
preparation method. By visual examination it was recognised that these phytosterol 
crystals grew in width rather than in length. It seems that the surface-active agent (1%, 
w/w) adsorbs selectively onto a specific crystal face and only retards, into some degree, 
the growth in length. Similar observations of specific adsorption have been made when 
crystallising e.g. carbamazepine (Luhtala, 1992). Usually only a small amount of a 
surface-active agent is required to bring noticeable changes to crystallisation phenomena, 
but, for some purposes, more than 1% is needed to achieve the desired effect (Canselier, 
1993). 
 
The differences in the compositions in phytosterol suspensions in oil not only affected the 
crystal size distribution and the habit but also the viscosity of the suspensions (I, Fig. 5 
and II). Phytosterol suspensions in oil in the absence of water caused nearly Newtonian 
flow behaviour since the anhydrous platy-like crystals have a tendency to align in the 
direction of the applied shear (Pena et al., 1995). Addition of 1% water did not affect the 
rheology of the suspension, even though the crystals were partially hydrated. The 
viscosity of the suspensions containing 5-13% water was considerably higher compared 
to the suspensions with plate-like crystals whereafter the viscosity systematically 
increased with higher phytosterol concentrations. Needle-shaped crystals have a tendency 
to aggregate. Yet a drastic decrease in viscosity was discovered with increasing shear rate 
due to rearrangement of the particles. This resulted in lower flow resistance and 
consequently lower viscosity (Pena et al., 1995; Zitoun et al., 2001). The viscosity of the 
suspension was also dependent on the phytosterol concentration. An increase in solid 
concentration limited the movement of the particles and increased the interactions 
between the particles, resulting in higher viscosity (Zitoun et al., 2001). The diminished 
viscosity with higher shear rates showed that the network formed by the particles was 
rather weak.   
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5.3.2 The effects of process parameters on crystal modifications (I,II, III)  
 
Effect of cooling temperature  
 
Cooling temperature turned out to have a remarkable effect on phytosterol particle size 
distribution in oil suspension due to the effect on supersaturation. Rapid crystallisation of 
phytosterol, produced by sudden cooling, resulted in the formation of needle crystals with 
a median crystal length of 23 µm. However, the suspensions still contained a distinct 
number of larger crystals (Fig. 12 and III, Fig. 2). With an increase in cooling 
temperature the crystal habit also changed to some degree. At low temperatures (≤10 °C), 
when the crystals were small, they were needle-like and even in shape and length, while 
they grew in width to a certain extent in increased temperatures (≥20 °C). Additionally 
the crystals were uneven in shape and length (III, Fig. 1).  
 
 
 
 
 
 
        
 Figure 12. Microscope images of phytosterol suspensions prepared by cooling at  
        (A) 0 °C (immersed in ice) and (B) 50 °C (bar =100 µm). 
 
A similar decrease in crystal length was observed when crystallising porcine insulin at 
different temperatures (Feldmeier et al., 1991). By increasing the cooling temperature 
from 0 °C to 30 °C, the average crystal length increased from 15 µm to 24 µm. Similarly, 
Motawi et al. showed that raising the temperature from 20 to 30 °C increased the rate of 
sulfathiazole crystal growth about 4.5 times (1982). At low cooling temperatures, the 
supersaturation level is high, resulting in an increased nucleation level and a large 
number of small crystals (Myerson and Ginde, 1993). The increase in the viscosity of the 
oil as the temperature decreased was a minor factor in our study. The diminished 
molecular movement slowed down both nuclei formation and the growth rate of the 
nuclei formed (Ebian et al., 1973; Mullin, 2001).  
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Effect of stirring rate and time 
 
Crystallisation at a low stirring rate (60 rpm) produced a few needle-shaped but mostly 
large platy-like crystals (median size 40 µm) (III, Fig. 3). By increased stirring (up to 250 
rpm), it was possible to achieve a nearly two-fold decrease in the median crystal size. The 
reduced phytosterol crystal size observed with stronger stirring was the result of 
increased secondary nucleation since crystal fragments acted as nucleation sites (Myerson 
and Ginde, 1993). Stirring is known to have a strong influence upon the nucleation rate 
until a particular stirring rate is reached. Similar results were obtained by Feldmeier et al. 
as increased stirring (from 0 rpm to 200 rpm) reduced the crystal size of porcine insulin 
roughly three-fold (1991).  
In addition, the stirring time has an influence on the crystal habit and size distribution. 
With increased stirring time, the length of the phytosterol crystals decreased (III, Fig. 4). 
The main recrystallisation in the oil suspension appeared at around 60 °C. If the agitation 
was stopped at higher a temperature, large crystals with a median crystal length of 38 µm 
were obtained. When stirring continued until the phytosterol suspension had reached 
room temperature (25 °C), the median crystal size was less than 20 µm.  
5.3.3 Changes in crystal size distribution and crystal habit during storage (II) 
 
Suspensions containing different amounts of phytosterol were stored at two different 
temperatures (+4 °C and -19 °C) for 16 weeks (II). The stability study showed that the 
viscosity of the suspensions seemed to have an influence on crystal length during storage 
although the crystal habit remained the same. Suspensions containing 5% (w/w) 
phytosterol had a much lower viscosity than the two other suspensions made with higher 
concentrations (II, Fig. 4). In 16 weeks the median phytosterol crystal length in this 
suspension increased from ~40 µm to ~60 µm when stored at +4 °C. With increasing 
sterol concentration and consequently at higher viscosity (see also section 4.3.1), the 
diffusion-controlled process involved in the crystal growth was retarded. Thus, there was 
no change in crystal size distribution in suspensions containing 17% and 30% 
phytosterol.  
On the other hand, phytosterol crystals in suspensions stored at -19 °C did not change in 
size during the period of storage at any concentrations. Equally, lower temperatures 
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decreased the molecular diffusion onto the surface of the particle, thereby affecting the 
crystal growth (Motawi et al., 1982). 
5.4 Effects on cholesterol solubilisation in vitro (V) 
 
Previously an in vivo study with 155 hypercholesterolemic volunteers has been performed 
to evaluate the cholesterol-lowering effect of the microcrystalline phytosterol suspension 
(Christiansen et al., 2001a). The in vitro study was performed to understand the 
mechanism by which phytosterols interfere with cholesterol absorption. The study was 
performed using a similar suspension as in the in vivo study, containing either a medium 
chain or long chain triglyceride.   
 
In vitro digestion of cholesterol and/ phytosterol during lipolysis  
 
The prediction of the solubilisation profile for a poorly water-soluble compound in a lipid 
formulation is complex and cannot be accurately achieved using simple dispersion 
methods. Recently various in vitro lipolysis methods have been used as models of 
solubilisation of water-insoluble substances (Trautwein et al., 2003; Zangenberg et al., 
2001a; Zangenberg et al., 2001b). Digestion experiments with LCT or MCT lipids 
containing either cholesterol or phytosterol were made to establish their individual 
solubilisation behavior.  
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Solubilisation of co-administered phytosterol and cholesterol into mixed 
micelles. The sterols were suspended in either LCT or MCT (n=3) (V, Figure 2). 
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The mixed micellar phase containing digestion products of LCT was able to incorporate 
significantly higher amounts of cholesterol than those obtained after digestion of MCT 
(IV, Fig. 1a). Replacing the long chain length triglyceride with one containing medium 
chain length fatty acids decreased the amount of solubilised cholesterol by 50% in the 
aqueous phase. Similar serum reduction has been observed earlier in vivo with both 
cholesterol and fat-soluble vitamins following ingestion of MCT compared to LCT 
(Kritchevsky and Tepper, 1965; Borel et al., 1998).  
Co-administration of phytosterol and cholesterol, particularly when suspended in MCT, 
showed a significant reduction of solubilised cholesterol in digests using cholesterol-free 
micelles (Fig. 13 and IV, Fig. 2). The amount of cholesterol solubilised into the micellar 
phase was further reduced to ~24% of the administered dose. Digestion of co-
administered phytosterol and cholesterol suspensions in either LCT or MCT was 
performed to simulate dietary intake of both sterols and to study the capacity of 
phytosterol to reduce cholesterol solubilisation. Despite the promising results with co-
administered sterols, it was not possible to displace pre-solubilised cholesterol during 
digestion in either MCT or LCT systems (IV, Fig. 3). These results were supported by the 
solubility studies (IV, Fig 4). Mel’nikov et al. showed in their study that phytosterols and 
phytostanols were able to compete with and displace pre-solubilised cholesterol from 
mixed micelles (2003b). This is explained by the saturated micelles ascribable to higher 
concentrations of lipolysis products. The pre-solubilised micelles were used to simulate 
the presence of endogenous cholesterol. 
When cholesterol and phytosterols are simultaneously present in the intestinal lumen 
during lipid digestion, it seems that both will be solubilised by the mixed micelles. 
However, it is obvious that phytosterols, together with MCT, act as a more efficient 
limiting factor of the micelle’s capacity to solubilise cholesterol. Thus, the results suggest 
that micelles, containing MCT digest products, would provide a more effective 
cholesterol-lowering agent compared to LCT. In addition to the transporter-associated 
mechanisms, the dynamic competition between these two sterols is one of the 
mechanisms contributing to the reduction of cholesterol absorption.  
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6 CONCLUSIONS 
 
In the present study, preparation of a microcrystalline phytosterol suspension in oil and 
water is described. By changing the amount of sterol and water, it was possible to 
influence the crystal habit and size distribution. Without added water, anhydrous plate-
like crystals were achieved. Addition of water to the composition produced mostly 
needle-shaped monohydrated crystals. Monohydrated crystal form is unstable and 
dehydrates to a hemihydrated form at a low temperature. Dehydration was similar both 
from plain crystals and crystals suspended in oil. The early onset of dehydration is 
characteristic of channel hydrates and it appears that water molecules are weakly bonded. 
Due to supersaturation, higher sterol concentrations resulted in the formation of small 
crystals. No changes in crystal habit, size distribution or crystal form were observed 
during storage of these small crystal sized suspensions, at either +4 °C or -19 °C for four 
months. A microcrystalline particle size was desirable to avoid a gritty feeling in the 
mouth. In addition to the saturation level, optimisation of the preparation process had a 
great impact on the crystal size distribution and crystal habit as well. By changing the 
process parameters, i.e. cooling temperature and stirring, it was possible to achieve the 
optimum crystal size for a so-called creamy suspension. In addition to phytosterol, the 
choice of lipid in the suspensions was observed to have a significant effect on 
solubilisation of sterols into the mixed micelles. The dynamic in vitro studies, in which 
medium and long chain length lipids were compared, showed that phytosterols 
formulated in MCT efficiently displaced cholesterol from mixed micelles, thereby 
contributing to the reduction of intestinal cholesterol absorption. Solubilisation into 
intestinal mixed micelles is a prerequisite for sterols to reach the site of absorption. As a 
result, the cholesterol absorption is decreased, which agrees with previous in vivo studies 
with a similar suspension.  
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